title: HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells.
abstract: Histone deacetylase (HDAC) inhibitors induce chromatin destabilization. We sought to determine whether HDAC inhibition may amplify alkylator-induced mitotic cell death in multiple myeloma (MM) cells. The combination of SNDX-275, a class I HDAC inhibitor, with melphalan, showed a powerful synergism on growth inhibition with the combination index ranged from 0.27 to 0.75 in MM1.S and RPMI8226 cells. Their combinations as compared with either agent alone promoted much more caspase-dependent apoptosis. Flow cytometry analysis showed that SNDX-275 had minimal effects on cell cycle progression of MM1.S cells, but clearly increased the percentage of S phase in RPMI8226 cells associated with an upregulation in p21(waf1) and a reduction in cyclin D1 and E2F1. Melphalan alone significantly arrested both MM1.S and RPMI8226 cells at S phase and enhanced expression of p53 and p21(waf1). Furthermore, studies on DNA damage response revealed that phospho-histone H2A.X (gammaH2A.X), a hall marker of DNA double strand break, along with phosphorylated CHK1 (P-CHK1) and CHK2 (P-CHK2) was dramatically induced by SNDX-275 or melphalan. The increase in gammaH2A.X and P-CHK1 was considerably higher on combination than either agent alone. These molecular changes correlated well with the significant increase in mitotic catastrophe. Our data indicate that SNDX-275 synergistically enhances melphalan-induced apoptosis in MM cells via intensification of DNA damage, suggesting that SNDX-275 in combination with melphalan may be a novel therapeutic strategy for MM.
authors.affiliation: Department of Medicine, University of Colorado Denver School of Medicine, Aurora, 80045, USA. choon-kee.lee@ucdenver.edu
authors.forename: Choon-Kee
authors.initials: CK
authors.lastname: Lee
authors.forename: Shuiliang
authors.initials: S
authors.lastname: Wang
authors.forename: Xiaoping
authors.initials: X
authors.lastname: Huang
authors.forename: John
authors.initials: J
authors.lastname: Ryder
authors.forename: Bolin
authors.initials: B
authors.lastname: Liu
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor / Q000187:drug effects; D004249:DNA Damage / Q000187:drug effects*; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use*; D008938:Mitosis / Q000187:drug effects; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology
chemical_list: D056572:Histone Deacetylase Inhibitors; D008558:Melphalan
references.citation: Cancer Sci. 2008 Feb;99(2):376-84
references.pmid: 18201278
references.citation: Blood. 2003 May 15;101(10):4055-62
references.pmid: 12531799
references.citation: Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6066-71
references.pmid: 15447991
references.citation: Cancer Res. 2002 Nov 1;62(21):6108-15
references.pmid: 12414635
references.citation: Adv Enzyme Regul. 1984;22:27-55
references.pmid: 6382953
references.citation: Cancer Res. 2003 Nov 1;63(21):7291-300
references.pmid: 14612526
references.citation: Best Pract Res Clin Haematol. 2007 Dec;20(4):797-816
references.pmid: 18070720
references.citation: Curr Biol. 2010 Mar 9;20(5):387-96
references.pmid: 20188555
references.citation: Cancer Res. 2006 Dec 1;66(23):11298-304
references.pmid: 17145876
references.citation: Clin Exp Metastasis. 2008;25(2):183-9
references.pmid: 18058245
references.citation: Oncogene. 2007 Aug 13;26(37):5541-52
references.pmid: 17694093
references.citation: J Biol Chem. 1977 Sep 25;252(18):6438-42
references.pmid: 893418
references.citation: Br J Haematol. 2001 Dec;115(3):522-40
references.pmid: 11736932
references.citation: Cancer Res. 2006 Jun 1;66(11):5781-9
references.pmid: 16740717
references.citation: Int J Cancer. 2004 Nov 1;112(2):171-8
references.pmid: 15352027
references.citation: Nat Rev Cancer. 2006 Jan;6(1):38-51
references.pmid: 16397526
references.citation: J Cell Biochem. 2009 Jul 1;107(4):600-8
references.pmid: 19459166
references.citation: Cell. 2007 Feb 23;128(4):693-705
references.pmid: 17320507
references.citation: Neoplasia. 2005 Jul;7(7):646-57
references.pmid: 16026644
references.citation: Leukemia. 2009 Jan;23(1):10-24
references.pmid: 18843284
references.citation: Nat Rev Cancer. 2007 Aug;7(8):585-98
references.pmid: 17646864
references.citation: Nat Rev Drug Discov. 2006 Sep;5(9):769-84
references.pmid: 16955068
references.citation: Cancer Res. 2009 Jun 15;69(12):5015-22
references.pmid: 19491273
references.citation: Curr Opin Genet Dev. 1999 Apr;9(2):171-4
references.pmid: 10322142
references.citation: Haematologica. 2006 Feb;91(2):248-51
references.pmid: 16461312
references.citation: J Natl Cancer Inst. 2006 Aug 16;98(16):E2
references.pmid: 16912255
references.citation: Cancer Res. 2008 Aug 15;68(16):6718-26
references.pmid: 18701496
references.citation: J Clin Oncol. 2005 Sep 10;23(26):6345-50
references.pmid: 16155018
references.citation: J Cell Biochem. 2005 Apr 15;94(6):1088-102
references.pmid: 15723344
references.citation: Arch Physiol Biochem. 2009 May;115(2):49-57
references.pmid: 19234898
references.citation: Blood. 2006 Nov 15;108(10):3441-9
references.pmid: 16728695
references.citation: Nature. 2003 Jan 30;421(6922):499-506
references.pmid: 12556884
references.citation: N Engl J Med. 2004 Oct 28;351(18):1860-73
references.pmid: 15509819
references.citation: Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1241-6
references.pmid: 14734806
references.citation: Cancer Res. 2009 Nov 1;69(21):8403-11
references.pmid: 19826038
references.citation: Clin Cancer Res. 2004 Jun 1;10(11):3839-52
references.pmid: 15173093
references.citation: Blood. 2003 Oct 1;102(7):2615-22
references.pmid: 12816865
references.citation: Cancer Res. 2003 Jul 1;63(13):3637-45
references.pmid: 12839953
references.citation: Oncogene. 2007 Aug 13;26(37):5310-8
references.pmid: 17694074
references.citation: Blood. 2009 May 7;113(19):4614-26
references.pmid: 19228610
references.citation: Mol Cancer Res. 2007 Oct;5(10):981-9
references.pmid: 17951399
references.citation: Clin Cancer Res. 2009 Mar 15;15(6):1998-2009
references.pmid: 19276263
references.citation: J Cell Biol. 2007 Sep 24;178(7):1101-8
references.pmid: 17893239
references.citation: Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):540-5
references.pmid: 14695887
references.citation: Curr Opin Genet Dev. 2005 Oct;15(5):490-5
references.pmid: 16098738
references.citation: Leukemia. 2004 Jul;18(7):1207-14
references.pmid: 15116122
references.citation: Cancer Cell. 2007 Sep;12(3):252-65
references.pmid: 17785206
references.citation: Exp Cell Res. 2007 Jul 1;313(11):2378-88
references.pmid: 17462628
references.citation: Leukemia. 2005 Oct;19(10):1729-38
references.pmid: 16094421
references.citation: Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4592-7
references.pmid: 10200307
references.citation: Oncogene. 2005 Jul 7;24(29):4609-23
references.pmid: 15897906
references.citation: Exp Hematol. 2003 Apr;31(4):271-82
references.pmid: 12691914
references.citation: Blood. 2007 Apr 1;109(7):2781-90
references.pmid: 17179232